Fung, ScottKwan, PeterFabri, MilotkaHorban, AndrzejPelemis, MijomirHann, Hie-WonGürel, SelimCaruntu, Florin A.Flaherty, John F.Massetto, BenedettaDinh, PhillipCorsa, AmoreenaSubramanian, G. ManiMcHutchison, John G.Husa, PetrGane, Edward2024-08-152024-08-152014-04-010016-5085https://doi.org/10.1053/j.gastro.2013.12.028https://www.sciencedirect.com/science/article/abs/pii/S0016508513018428https://hdl.handle.net/11452/44065BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited.METHODS: In a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n 139) and TDF (300 mg, FTC/TDF). Patients were hepatitis B e antigen (HBeAg) - positive or HBeAg-negative, with levels of HBV DNA >= 3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V +/- rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA). The primary end point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA).RESULTS: Patient groups were well matched for demographic and disease characteristics, including region (60% from Europe), HBV genotype (45% genotype D), HBeAg status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years). At week 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43). HBeAg loss and seroconversion did not differ between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen. Treatment was well tolerated; confirmed renal events (creatinine increase of >= 0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/dL [<0.65 mmol/L]) were generally mild and infrequent (<1%). Small reductions (<2%) in mean bone mineral density of hip and spine were detected by dual-energy x-ray absorptiometry in both groups. No TDF resistance developed through 96 weeks of treatment.CONCLUSIONS: TDF alone is safe and effective for treatment of patients with lamivudine-resistant, chronic HBV infection. Clinical Trials.gov No, NCT00737568.eninfo:eu-repo/semantics/closedAccessBone-mineral densityGenotypic resistanceCombination therapyNucleotide analogsAdefovir dipivoxilTurnover markersNaive patientsEntecavirVirusManagementHbv dnaHepatitis b e antigenRenal functionViral suppressionGastroenterology & hepatologyArticle000333254500027980U521146410.1053/j.gastro.2013.12.028